Skip to main
IDXX

IDEXX Laboratories (IDXX) Stock Forecast & Price Target

IDEXX Laboratories (IDXX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

IDEXX Laboratories is a global leader in animal health diagnostics and software. It has a strong recurring revenue model with over 35% of its revenue coming from outside the United States, and its core companion animal segment represents over 90% of its total revenue. It has consistently outperformed industry averages for revenue growth and has a strong customer retention rate of around 97%. The stock may trade at a premium valuation, but IDEXX's strong performance and position in the market make it a solid long-term investment opportunity.

Bears say

IDEXX Laboratories is a leading veterinary diagnostics company, but faces risks including competition, complex manufacturing, government regulation, consolidation, inexperience in human diagnostics, and potential impact from macroeconomic headwinds. Despite potential easing of these issues, clinical office visits continue to decline, and the company faces challenges with staffing shortages and inflation that may impact growth. Additionally, while IDEXX has a large and productive salesforce and continues to invest in R&D, there is some degree of competition in the animal health industry.

IDEXX Laboratories (IDXX) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IDEXX Laboratories (IDXX) Forecast

Analysts have given IDEXX Laboratories (IDXX) a Buy based on their latest research and market trends.

According to 9 analysts, IDEXX Laboratories (IDXX) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $721.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $721.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IDEXX Laboratories (IDXX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.